We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!
As part of a nationwide study, Clinvest and Missouri State University are working to improve the way in which we evaluate the impact of migraine on patient’s lives. We are looking for participants who can help shed some insight into the important factors patients use to evaluate their own response to treatment. This online survey will ask questions to find our more information about your migraines, treatment, and what you feel are the most important components to feeling better. It should take no longer than 60 minutes to complete the survey requirements.The end result of this project will be a preliminary questionnaire that will help patients and clinicians evaluate the impact of migraine on their lives.
The purpose of this study is to determine the benefit of taking 300mg of an investigational drug compared to the currently approved 150mg dose for patients with Ankylosing Spondylitis (AS). Qualifying volunteers would come to our office for approximately 19 visits over a 52-week period. Patients will be given 16 doses of the investigational drug during the course of the study.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of investigational medication for the Acute Treatment of Episodic Migraine in Adolescents. Qualified patients ages 12-17 will attend up to 3 visits and treat up to 2 migraines over 28 weeks with study medication.
This research study is to compare the duration, safety, and effectiveness of the investigational study medication (Fremanezumab) to placebo (an inactive look-alike). Qualified volunteers will be randomly assigned to receive study medication or placebo. Completion of the study would involve coming to our office for 7 appointments, over a 44-week period. Subjects will receive 3 doses of investigational product or placebo during the study.
The study is for subjects 18 and older. The study duration is up to 3 years. Subject will receive both oral study drug once daily and subcutaneous study drug every other week. Period 1 is 56 weeks and 13 site visits. Subject will have a site visit at week 56 and every 12 weeks thereafter.
The research study is available for participants 18 and older. The subject will take the study drug once daily. There are 13 office visits in Period 1. The study duration is up to 3 years. Subject will have a study visit at week 56 and every 12 weeks thereafter.
Clinvest Research is currently enrolling participants for a phase 3 clinical study investigating a new selective JAK1 inhibitor for Rheumatoid Arthritis. Participants need to be over 18 years of age, have diagnosis of Rheumatoid Arthritis, have had an inadequate response or intolerant to previous treatments, and on a stable dose of a Synthetic Disease Modifying Anti-Rheumatic Drug. The study is up to 5 years in duration. Compensation for time and travel may be provided and study related care is at no cost.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine.